IQVIA

709 articles with IQVIA

• IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021

  5/20/2021

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ron Bruehlman, executive vice president and chief financial officer, will participate in a virtual fireside chat at the William Blair Growth Stock Conference on Wednesday, June 2, 2021 at 10:20 a.m. EDT.

• Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science

  5/19/2021

  Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA™ Institute for Human Data Science.

• U.S. District Court Issues Favorable Decision for IQVIA Against Veeva

  5/10/2021

  IQVIA (NYSE:IQV), a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (NYSE:VEEV).

• IQVIA’s Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug

  5/3/2021

  IQVIA (NYSE: IQV) announced today that it will collaborate with Corium, Inc – a commercial-stage biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies – to support the launch of AZSTARYS™, which was approved by the U.S. FDA on March 2, 2021.

• Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study

  4/29/2021

  The two leading global therapy areas — oncology and immunology — are forecast to grow 9-12% CAGR through 2025, lifted by significant increases in new treatments and medicine use

• IQVIA Announces Connected Intelligence™

  4/28/2021

  IQVIA (NYSE: IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, today announced Connected Intelligence™, its innovative approach to enabling life sciences customers to discover powerful new insights, drive smarter decision-making, and get treatments to patients faster.

• Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

  4/6/2021

   Moleculin Biotech, Inc., today announced the engagement of IQVIA Biotech, a contract research organization (CRO) to manage the Company's effort to begin potential clinical trials of WP1122 for the treatment of COVID-19.

• IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance

  4/1/2021

  IQVIA Acquires Remaining Interest in Q 2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance  

• IQVIA Virtual Trial Solutions Used in More than 60 Trials

  3/9/2021

  IQVIA™ announced that more than 60 trials spanning over 40 countries utilize its innovative decentralized clinical trial solutions as part of their respective registration trials.

• IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials

  3/8/2021

  IQVIA™ (NYSE: IQV) announces that since September 2020 it has been collaborating with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, on the Phase 3 COVID-19 vaccine clinical trials. The studies leverage IQVIA’s suite of decentralized trial solutions that support both on-site and remote study delivery through a mix of tel

• IQVIA Announces Pricing of Offering of Senior Notes - Feb 17, 2021

  2/17/2021

  IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €1,450,000,000 in aggregate principal amount of senior notes, consisting of €550,000,000 in aggregate principal amount of senior notes due 2026 and €900,000,000 in aggregate principal amount of senior notes due 2029.

• IQVIA Announces Offering of Senior Notes - Feb 16, 2021

  2/16/2021

  IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., intends to raise €1,450,000,000 in gross proceeds through an offering of senior notes due 2026 and senior notes due 2029.

• IQVIA Reports Fourth-Quarter and Full-Year 2020 ResultsRaises Full-Year 2021 Guidance

  2/10/2021

  IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance Revenue of $3,298 million for the fourth quarter grew 13.9 percent year-over-year Adjusted EBITDA of $735 million for the fourth quarter increased 14.5 percent year-over-year

• IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report

  2/4/2021

  IQVIA™ (NYSE: IQV) today announced that it has been recognized as a top performer by survey respondents in Industry Standard Research’s eCOA/ePRO Market Dynamics and Service Provider Performance (4th Edition) report for overall performance, capabilities, cost, system flexibility and support, system/device integration, and validation and patient compliance.

• IQVIA Named to FORTUNE’s 2021 List of “World’s Most Admired Companies”

  2/1/2021

  IQVIA Holdings Inc. has been named to FORTUNE magazine’s “World’s Most Admired Companies” list.

• IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021

  1/26/2021

  IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its fourth-quarter and full-year 2020 financial results before the market opens on Wednesday, February 10, 2021. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that date.

• Laboratoires Théa Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation

  1/5/2021

  IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, announced that Laboratoires Théa, the leading independent eye care group in Europe, has selected IQVIA Technologies’ Orchestrated Customer Engagement platform and the OneKey HCP/HCO reference database for deployment across more than 22 markets.

• IQVIA and Servier Collaborate to Reinvent Clinical Development

  12/16/2020

  IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a collaboration with Servier, an independent global pharmaceutical company, to reinvent their R&D clinical development processes and support their long-term R&D success. Servier has ambitious plans for growth a

• IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence

  12/7/2020

  IQVIA™ said that it is pleased to be a supporter of the Real World Evidence Leadership Forum, a group consisting of senior RWE executives from 18 major pharmaceutical companies.

• IQVIA’s Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities

  11/2/2020

  IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Zentiva, a leading player in branded generic and OTC medications in the European and CIS markets, is leveraging IQVIA’s Orchestrated Customer Engagement (OCE) platform across 12 major markets. The platform will be key to helping Z